Credit Suisse analyst A.J. Rice lowered the firm’s price target on Amedisys to $115 from $140 and keeps an Outperform rating on the shares. The analyst notes labor is not expected to show meaningful improvement in 2023, which leads him to a more conservative view on the volume growth outlook. Regarding 2023 guidance, Rice expects management to guide with a conservative bias.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AMED:
- Amedisys to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Computerworld Names Amedisys to 2023 List of Best Places to Work in IT
- Amedisys closes on home health JV with University of Arkansas
- Amedisys Completes Home Health Joint Venture with the University of Arkansas for Medical Sciences
- Amedisys is Named One of the Most Responsible Companies of 2023 by Statista and Newsweek
